Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells 2,958 Shares of Stock

TransMedics Group, Inc. (NASDAQ:TMDX) insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $156.77, for a total value of $463,725.66. Following the completion of the sale, the insider now directly owns 20,843 shares of the company’s stock, valued at approximately $3,267,557.11. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

TransMedics Group Stock Performance

Shares of NASDAQ TMDX traded down $1.65 during midday trading on Monday, hitting $148.45. The company’s stock had a trading volume of 1,121,093 shares, compared to its average volume of 760,775. The company has a debt-to-equity ratio of 3.18, a quick ratio of 8.76 and a current ratio of 9.72. The firm’s fifty day moving average price is $144.02 and its 200-day moving average price is $111.51. The firm has a market cap of $4.89 billion, a P/E ratio of -441.47 and a beta of 1.99. TransMedics Group, Inc. has a 1-year low of $36.42 and a 1-year high of $171.98.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.14. The business had revenue of $114.30 million for the quarter, compared to analyst estimates of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 17.37%. The firm’s revenue was up 117.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.03) earnings per share. On average, sell-side analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds have recently made changes to their positions in the business. Pitcairn Co. boosted its stake in shares of TransMedics Group by 1.5% in the 1st quarter. Pitcairn Co. now owns 5,378 shares of the company’s stock valued at $398,000 after purchasing an additional 78 shares during the last quarter. Signaturefd LLC boosted its position in shares of TransMedics Group by 26.6% in the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after acquiring an additional 93 shares during the period. Arizona State Retirement System raised its stake in TransMedics Group by 2.1% in the second quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock valued at $1,379,000 after purchasing an additional 186 shares in the last quarter. First Horizon Advisors Inc. raised its stake in TransMedics Group by 26.8% in the fourth quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock valued at $83,000 after purchasing an additional 222 shares in the last quarter. Finally, International Assets Investment Management LLC acquired a new position in TransMedics Group during the second quarter worth about $47,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on TMDX shares. Morgan Stanley boosted their price objective on TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Cantor Fitzgerald began coverage on TransMedics Group in a report on Thursday, June 6th. They set an “overweight” rating and a $161.00 price objective for the company. Stephens increased their price target on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research report on Friday. Canaccord Genuity Group raised their target price on TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Piper Sandler raised their target price on shares of TransMedics Group from $170.00 to $180.00 and gave the stock an “overweight” rating in a research note on Thursday. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $166.88.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.